| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 07/31/2026 | ±2.9% | -0.3% | over-priced |
| 05/01/2026 | ±1.8% | +2.2% | under-priced |
| 10/31/2025 | ±1.6% | +0.7% | over-priced |
| 08/01/2025 | ±2.0% | -0.4% | over-priced |
| 04/25/2025 | ±2.6% | +1.3% | over-priced |
| 10/25/2024 | ±1.3% | -4.1% | under-priced |
| 04/26/2024 | ±1.4% | +1.9% | under-priced |
| 10/27/2023 | ±1.4% | -1.8% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q2 FY2026 | $0.86 | $5.4B | $719M |
| Q1 FY2026 | $0.80 | $5.3B | $681M |
| Q4 FY2025 | $-0.04 | $5.2B | $-5M |
| Q3 FY2025 | $0.91 | $5.1B | $766M |
Colgate-Palmolive Company (CL) reports in 72 days, with the next report estimated for 11/23/2026. Across the last 8 reports, options priced an average ±1.9% earnings move while the stock actually moved 1.6% on average — the market has been roughly fair on CL's earnings risk. Fundamentals into the print: EPS down 5.5% year-over-year, revenue up 4.9%. QuantLogix's live 5-factor engine currently reads CL as a underweight at 43/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →